ES2663968T3 - Anticuerpo anti-NGF humano nuevo - Google Patents
Anticuerpo anti-NGF humano nuevo Download PDFInfo
- Publication number
- ES2663968T3 ES2663968T3 ES12821758.5T ES12821758T ES2663968T3 ES 2663968 T3 ES2663968 T3 ES 2663968T3 ES 12821758 T ES12821758 T ES 12821758T ES 2663968 T3 ES2663968 T3 ES 2663968T3
- Authority
- ES
- Spain
- Prior art keywords
- fab
- fragment
- antibody
- ngf
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011176209 | 2011-08-11 | ||
| JP2011176209 | 2011-08-11 | ||
| JP2011269215 | 2011-12-08 | ||
| JP2011269215 | 2011-12-08 | ||
| PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトｎｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663968T3 true ES2663968T3 (es) | 2018-04-17 |
Family
ID=47668585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12821758.5T Active ES2663968T3 (es) | 2011-08-11 | 2012-08-10 | Anticuerpo anti-NGF humano nuevo |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8986952B2 (https=) |
| EP (1) | EP2743348B1 (https=) |
| JP (1) | JP5376095B2 (https=) |
| KR (1) | KR101999867B1 (https=) |
| CN (1) | CN103748222B (https=) |
| AR (1) | AR087506A1 (https=) |
| AU (1) | AU2012293161B2 (https=) |
| BR (1) | BR112014002576B1 (https=) |
| CA (1) | CA2841181C (https=) |
| CY (1) | CY1119914T1 (https=) |
| DK (1) | DK2743348T3 (https=) |
| EA (1) | EA024292B1 (https=) |
| ES (1) | ES2663968T3 (https=) |
| HR (1) | HRP20180155T1 (https=) |
| HU (1) | HUE036079T2 (https=) |
| IL (1) | IL230797A (https=) |
| IN (1) | IN2014CN00614A (https=) |
| LT (1) | LT2743348T (https=) |
| ME (1) | ME02944B (https=) |
| MX (1) | MX351273B (https=) |
| NO (1) | NO2743348T3 (https=) |
| PH (1) | PH12014500001A1 (https=) |
| PL (1) | PL2743348T3 (https=) |
| PT (1) | PT2743348T (https=) |
| RS (1) | RS56876B1 (https=) |
| SI (1) | SI2743348T1 (https=) |
| SM (1) | SMT201800166T1 (https=) |
| TW (1) | TWI554519B (https=) |
| WO (1) | WO2013022083A1 (https=) |
| ZA (1) | ZA201400741B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ｎｇｆ組成物およびその使用 |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| CA2986210C (en) * | 2015-05-22 | 2022-04-26 | Astellas Pharma Inc. | Novel anti-human ngf antibody fab fragment |
| JPWO2017164349A1 (ja) * | 2016-03-25 | 2019-02-07 | アステラス製薬株式会社 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| EP3795176A4 (en) | 2018-05-15 | 2022-01-12 | Astellas Pharma Inc. | Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1994020632A1 (fr) | 1993-03-11 | 1994-09-15 | Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute | Anticorps monoclonal dirige contre le vih |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1401498T3 (da) | 2001-05-30 | 2011-11-21 | Genentech Inc | Anti-NGF-antistoffer til behandlingen af forskellige sygdomme |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN102408483B (zh) | 2003-07-15 | 2016-06-08 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2006077441A1 (en) | 2005-01-24 | 2006-07-27 | Cambridge Antibody Technology Limited | Specific binding members for ngf |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| SG175436A1 (en) | 2009-05-04 | 2011-12-29 | Abbott Res Bv | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
-
2012
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh not_active Expired - Fee Related
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja not_active Ceased
- 2012-08-10 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 SM SM20180166T patent/SMT201800166T1/it unknown
- 2012-08-10 PH PH1/2014/500001A patent/PH12014500001A1/en unknown
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh not_active IP Right Cessation
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko not_active Expired - Fee Related
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663968T3 (es) | Anticuerpo anti-NGF humano nuevo | |
| US9127055B2 (en) | Method of treating pain with anti-human NGF antibody | |
| ES2926773T3 (es) | Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular | |
| UA107341C2 (uk) | Молекули антитіл, що мають специфічність до людського ox40 | |
| IL301658A (en) | Drug compound consisting of antibody-drug conjugate and use of drug composition | |
| ES2665851T3 (es) | Nuevo anticuerpo anti-CTGF humano | |
| ES2343424T3 (es) | Procedimiento para potenciar o inhibir el factor de crecimiento 1 similar a la insulina. | |
| ES2726915T3 (es) | Nuevo anticuerpo anti-PAI-1 humano | |
| JP6700620B2 (ja) | 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント | |
| ES2701064T3 (es) | Novedoso anticuerpo antirreceptor IL-23 humano | |
| JP6135161B2 (ja) | 新規抗ヒトｎｇｆ抗体 | |
| ES2831651T3 (es) | Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento | |
| HK40090814A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 |